Compare · LUCD vs SYK
LUCD vs SYK
Side-by-side comparison of Lucid Diagnostics Inc. (LUCD) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCD and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.37B, about 644.8x LUCD ($196.0M).
- Over the past year, LUCD is down 16.2% and SYK is down 15.7% - SYK leads by 0.5 points.
- SYK has been more active in the news (9 items in the past 4 weeks vs 6 for LUCD).
- SYK has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- Lucid Diagnostics Inc.
- Stryker Corporation
- Price
- $0.96+0.32%
- $329.31+0.48%
- Market cap
- $196.0M
- $126.37B
- 1M return
- +1.80%
- +3.19%
- 1Y return
- -16.23%
- -15.70%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 9
- Recent ratings
- 6
- 25
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest LUCD
- PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
- Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
- SEC Form 10-Q filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
- Lucid Diagnostics to Participate in Upcoming Investor Conferences
- PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
- Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
- Lucid Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Matheis Dennis bought $245,270 worth of shares (245,000 units at $1.00), increasing direct ownership by 31% to 1,033,443 units (SEC Form 4)
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation